The Chhattisgarh health department is committed to zero tolerance regarding quality control, as stated. In line with this, the department has taken significant action by issuing a blacklisting show cause notice to M/s. Effi Parenterals. This action was taken after quality control tests revealed significant issues with the supplied medication.
Prior to supplying drugs from warehouses to health institutions, the CGMSCL conducts quality tests on random samples of all batches supplied by the suppliers using NABL-accredited labs. This ensures that only drugs that pass the tests are distributed within the health institutions.
As part of this process, Albendazole Tablets IP 400 mg (Drug Code – D12) supplied by M/s. Effi Parenterals to the warehouse, batches PGT25451, PGT25450, PGT25480, PGT25229, were tested at the State Drug Testing and Research Laboratory, Raipur, before being sent to hospitals. The tests revealed that these batches had failed. Consequently, adhering to the zero-tolerance policy on quality, a show-cause notice has been issued to the concerned firm for blacklisting. Additionally, the concerned firm has been instructed to recall all failed batches of the drug from the drug warehouses.
In addition to these batches, the firm had previously supplied 14 batches of Albendazole Tablets IP 400 mg, which were distributed to health institutions after passing NABL test reports.